5HT3 antagonism abolishes the emotion potentiated startle effect in humans

被引:49
作者
Harmer, CJ
Reid, CB
Ray, MK
Goodwin, GM
Cowen, PJ
机构
[1] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England
[2] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England
基金
英国医学研究理事会;
关键词
serotonin; emotion potentiated startle; 5HT receptor subtypes; emotional processing;
D O I
10.1007/s00213-006-0337-z
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: The serotonergic system has been implicated in emotional processing in animals and humans. Although the contribution of different receptor subtypes has been hypothesised, there have been few direct tests of this in human subjects. Objectives: The current study aimed to explore the involvement of the serotonin type 3 (5HT(3)) receptor subtype in a battery of emotional processing tasks previously found to be sensitive to SSRI administration. Materials and methods: Healthy volunteers were randomised to receive the 5HT(3) antagonist, ondansetron (12 mg, oral), or placebo in a double blind between groups design. Emotional processing was assessed using three tasks: affective modulation of the startle reflex, emotional categorisation and memory and facial expression recognition. Subjective state ratings, blood pressure and pulse were also collected before and after ondansetron and placebo. Results: Ondansetron was well tolerated and did not affect subjective measures of mood, anxiety or well-being in these healthy volunteers. However, the emotion potentiated effect was abolished in the volunteers receiving ondansetron. Facial expression recognition and emotional memory were not significantly affected. Conclusions: These results suggest an involvement of 5HT(3) receptors in certain aspects of fear processing in humans. These effects are consistent with anxiolytic actions of 5HT(3) antagonism in animal models and suggest that the 5HT(3) receptor may play a role in the effects of serotonergic manipulations on fear and anxiety.
引用
收藏
页码:18 / 24
页数:7
相关论文
共 28 条
  • [1] LIKABLENESS RATINGS OF 555 PERSONALITY-TRAIT WORDS
    ANDERSON, NH
    [J]. JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY, 1968, 9 (03) : 272 - &
  • [2] Acute administration of nutritionally sourced tryptophan increases fear recognition
    Attenburrow, MJ
    Williams, C
    Odontiadis, J
    Reed, A
    Powell, J
    Cowen, PJ
    Harmer, CJ
    [J]. PSYCHOPHARMACOLOGY, 2003, 169 (01) : 104 - 107
  • [3] Benzodiazepines have no effect on fear-potentiated startle in humans
    Baas, JMP
    Grillon, C
    Böcker, KBE
    Brack, AA
    Morgan, CA
    Kenemans, JL
    Verbaten, MN
    [J]. PSYCHOPHARMACOLOGY, 2002, 161 (03) : 233 - 247
  • [4] Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression
    Bhagwagar, Z
    Cowen, PJ
    Goodwin, GM
    Harmer, CJ
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (01) : 166 - 168
  • [5] Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635
    Bhagwagar, Z
    Rabiner, EA
    Sargent, PA
    Grasby, PM
    Cowen, PJ
    [J]. MOLECULAR PSYCHIATRY, 2004, 9 (04) : 386 - 392
  • [6] The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: A comparison with tianeptine
    Burghardt, NS
    Sullivan, GM
    McEwen, BS
    Gorman, JM
    LeDoux, JE
    [J]. BIOLOGICAL PSYCHIATRY, 2004, 55 (12) : 1171 - 1178
  • [7] Neuropsychology of fear and loathing
    Calder, AJ
    Lawrence, AD
    Young, AW
    [J]. NATURE REVIEWS NEUROSCIENCE, 2001, 2 (05) : 352 - 363
  • [8] DAVIS M, 1993, BRAZ J MED BIOL RES, V26, P235
  • [9] PET imaging of serotonin 1A receptor binding in depression
    Drevets, WC
    Frank, E
    Price, JC
    Kupfer, DJ
    Holt, D
    Greer, PJ
    Huang, YY
    Gautier, C
    Mathis, C
    [J]. BIOLOGICAL PSYCHIATRY, 1999, 46 (10) : 1375 - 1387
  • [10] Ekman P., 1976, PICTURES FACIAL AFFE